Table 5.
Adverse events
| Adverse event a | Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | Total | NC/NA, % |
|---|---|---|---|---|---|---|---|
| Injection site reaction | 16 | 0 | 0 | 0 | 0 | 16 | 38.5 |
| Fatigue | 8 | 3 | 0 | 0 | 0 | 11 | 57.7 |
| Fever | 7 | 2 | 0 | 0 | 0 | 9 | 65.4 |
| Nausea | 1 | 2 | 0 | 0 | 0 | 3 | 88.5 |
| Flu like symptoms | 3 | 0 | 0 | 0 | 0 | 3 | 88.5 |
| Weight loss | 1 | 1 | 0 | 0 | 0 | 2 | 92.3 |
| Malaise | 1 | 1 | 0 | 0 | 0 | 2 | 92.3 |
| Anorexia | 1 | 1 | 0 | 0 | 0 | 2 | 92.3 |
| Pain in extremity | 2 | 0 | 0 | 0 | 0 | 2 | 92.3 |
| Neck pain | 1 | 0 | 0 | 0 | 0 | 1 | 96.2 |
| Bone pain | 0 | 1 | 0 | 0 | 0 | 1 | 96.2 |
| Erythema | 1 | 0 | 0 | 0 | 0 | 1 | 96.2 |
| Aspartate aminotransferase increased | 0 | 1 | 0 | 0 | 0 | 1 | 96.2 |
| Dyspnea | 1 | 0 | 0 | 0 | 0 | 1 | 96.2 |
| Myalgia | 0 | 1 | 0 | 0 | 0 | 1 | 96.2 |
| Rash | 1 | 0 | 0 | 0 | 0 | 1 | 96.2 |
| Dizziness | 1 | 0 | 0 | 0 | 0 | 1 | 96.2 |
| Edema limbs | 1 | 0 | 0 | 0 | 0 | 1 | 96.2 |
| Alkaline phosphatase increased | 1 | 0 | 0 | 0 | 0 | 1 | 96.2 |
| Venous stasis | 1 | 0 | 0 | 0 | 0 | 1 | 96.2 |
| Blood bilirubin increased | 1 | 0 | 0 | 0 | 0 | 1 | 96.2 |
| Diarrhea | 1 | 0 | 0 | 0 | 0 | 1 | 96.2 |
| Headache | 1 | 0 | 0 | 0 | 0 | 1 | 96.2 |
| Total | 51 | 13 | 0 | 0 | 0 | 64 |
a
Listed adverse events are possible, probable, or certainly related.
Abbreviation: NC/NA, no change from baseline/no adverse event.